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Abstract  
AIM: The aim of this study was to analyze the use of benzodiazepines in the period of 2003-2013 
year in the Republic of Macedonia (MKD). 
METHOD: The study was cross sectional and analyzes the available data on the use of 
benzodiazepines in the country. This study used several sources of data: Statistical Reports of the 
United Nations regarding the consumption of psychotropic substances; data from the Ministry of 
Health associated with the use of benzodiazepines (BZD), derived from reports of Ministry of Health 
stakeholders; Data extracted from the database of the Ministry of Health in the electronic database 
"My term" and Analysis of reports of Health Insurance Fund. 
RESULTS: The analysis for the period 2003-2013 showed that the most consumed drug in MKD 
from the group of BZD is Diazepam, with 54.8 and predominantly is use of diazepam of 5 mg with 
59 %. According to the Health Insurance Fund, Diazepam is second most prescribed medicaments 
of all medicaments with marketing authorization in MKD. 
CONCLUSIONS: The analysis shows that the use of BZD in MKD is particularly high. Limited 
number of studies was performed for this kind of drugs relating to their effects; differences in use 
between genders; adult population. There is need for additional focused research that will 
contribute to developing a full picture of the situation. 
 
 
 
 
 
Introduction 
 
Benzodiazepines are used to treat anxiety, 
insomnia, seizures, muscle spasms, alcohol 
withdrawal and as a premedication for medical or 
dental procedures [1]. Benzodiazepines influence to 
increase the effect of the neurotransmitter gamma-
amino butyric acid (GABA) acts by facilitating the 
binding of the inhibitory neurotransmitter GABA in 
different GABA receptors in the CNS, resulting in 
sedative, hypnotic action, encourages sleep, 
anxiolytic, anti-anxiety, anticonvulsant and muscle 
relaxant properties [2]. In the group of 
benzodiazepines with the United Nations Conventions 
on drug control [3] 34 substances are classified. 
Thirty-three BZD are included in the list of Convention 
IV, and 22 of these are classified as BZD anxiolytics. 
In the last decade, the total production of these 
substances ranges from 19.4 billion and 29.9 billion S-
DDD statistically calculated Defined Daily Dose [4], 
calculated per year for the period 2003 to 2011.  
In 2012 the highest consumption on a 
worldwide scale is marked the BZD alprazolam, which 
covers 29% (4.6 billion S-DDD, the total amount of 
produced type BZD anxiolytics; Diazepam covers 26% 
(4.3 billion S-DDD), lorazepam 21% (3.3 billion S-
DDD); bromazepam 8% (1.3 billion S-DDD) and 
others. Between 2003-2012 the largest manufacturers 
worldwide BZD are placed in China (1.9 billion S-
DDD), India and Italy (7 billion S-DDD) [5]. According 
to the United Nations, Diazepam is still the most used 
psychotropic substances of the BZD anxiolytics and it 
is used in all regions of the world for medical purposes 
and very frequently is observed misuse and diversion 
to illegal purposes. Though the highest level of 
diazepam produced worldwide was 113 tons in 2004, 
according to statistics from the United Nations, the 
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quantity in the following years shows a drastic decline 
in production, but this medicine is still widely used. 
Countries that emphasize  the most used diazepam in 
2012 counted in statistics calculated Defined Daily 
Dose per 1000 inhabitants are in Ghana (61,5 S-
DDD), Croatia (35,8 S-DDD), Macedonia (23,2 S-
DDD) and Uruguay (18,9 S-DDD) [4]. In the group of 
BZD sedative - hypnotics are twelve psychotropic 
substances, of which MKD marketed flurazepam, 
midazolam, nitrazepam, temazepam. The biggest 
producers of this group of substances are USA, 
Germany, Italy and Switzerland.  
To have a complete picture of where does the 
great medical use of drugs from the group of BZD, 
and perceived independent, non-medical use of 
medicines of this type, the paper provides a brief 
overview of pharmacological effect of these 
medicines. No medical use and abuse of drugs 
prescription is present as a general condition in all 
countries, regardless of interventions, health 
authorities, health professionals, regulatory 
institutions. But the phenomenon is the combined 
prescription of medicines from BZD group and opioid 
analgesics. There are pharmacokinetic interactions 
between benzodiazepines and opioid analgesics. 
Complex pharmacodynamic effects of these drugs 
vary and their combined effects are able to produce 
significant respiratory depression [6]. Moreover, 
considering the existence of an opportunity for self-
purchase of drugs in pharmacy, health workers have 
to inform patients about possible overdose by taking a 
combination of drugs especially in these categories 
[6]. Use of this group of drugs for a long-time shows 
that orally taken BZD without additionally consumed 
substances (such as other drugs, alcohol, etc.), can 
rarely cause significant morbidity or mortality. But in 
mixed overdoses, they may potentiate the effect of 
alcohol or other sedative hypnotics. BZD overdose 
often occurs in association with other substances. In 
2011, a total of 82,086 BZD exposure as the single 
substance reported to the U.S. Centers for control of 
poisoning, 300 (0.004%) resulted in major toxicity and 
15 (0.0001%) resulted in death [7]. The World Health 
Organization suggests that drug interactions are a 
leading cause of morbidity and mortality [8].  
We can’t neglect the data imply that drugs of 
the benzodiazepine group extensively used by people 
who have developed a drug addiction. On this topic 
are conducted numerous researches aimed to 
determine the reasons for the use of BZD by these 
individuals, whether the reason is the existence of 
psychiatric co-morbidity and/or only to supplement the 
amount of opiates/opioids is of interest to implement 
additional medical stream. The scientific research 
conducted, demonstrated that most patients addicted 
to drugs have additional, besides reliability, at least 
one severely impaired health disorder - psychiatric co-
morbidity. The study conducted in Baltimore, USA, 
during the three-year analysis of patients on treatment 
for drug addiction showed that 60.6% of patients with 
dependence on psychoactive substances are present 
in psychiatric co- morbidity, and more than 30% have 
at least two psychiatric disorders [9]. Studies show 
higher rates of psychiatric co-morbidity in people who 
are dependent on cannabis (76%) in compared 
addiction with heroin and cocaine (60%). The rate of 
use of benzodiazepines is high among persons with 
severe mental illness and co-morbidity of drug 
addiction, as well as in patients with severe mental 
illness, only [10]. 
Members of the females appear significantly 
more psychiatric disorder, compared with members of 
the male sex (73.7% in comparison with 55.4%) [11]. 
There was an association between depressive 
symptoms with worse patient outcomes from 
treatment, suggesting the need for attention to 
depressive symptoms and subjective distress in order 
better clinical approach to the treatment of substance 
abuse and consequently improve the results of 
treatment [12]. As a result, many patients with opioid 
dependence require treatment with psychotropic 
drugs, also. Great use and abuse of anxiolytic drugs, 
benzodiazepines and sedative-hypnotics by persons 
with opioid dependence who are on substitution 
treatment is perceived phenomenon. 
Concerns for the use of BZD together with 
substitution therapy for the treatment of drug addiction 
are coming from the mechanism of action of these 
drugs. The opioids, including methadone, inhibit the 
action of breathing through medullar part receptors, 
the respiratory center. Benzodiazepines (and also 
alcohol is often used in combination) act 
synergistically through these mechanisms of action 
and this may explain the possibility of fatal overdose 
in the presence of opioids and benzodiazepines and / 
or alcohol [13].  Studies show that the most commonly 
used benzodiazepine - diazepam is not associated 
with a change of methadone concentrations in 
plasma, but reported significant pharmacodynamic 
interactions between diazepam and methadone and 
diazepam and buprenorphine [14-15]. Diazepam is 
associated with increased sedation, and weakened 
performance in conducting psychological tests. On the 
other hand the fatal consequences may occur with 
concomitant use of methadone and alprazolam (also 
BZD, which last period is used often) [16], where the 
concentration of methadone in the blood confirmed 
findings in the toxic range, suggests that the 
pharmacodynamic interaction between methadone 
and alprazolam emphasize toxicity [17-18]. Morbidity 
and mortality that is associated with co-ingestion of 
methadone or buprenorphine and BZD suggests that 
caution should be particularly cautious in prescribing 
benzodiazepines for those receiving methadone or 
buprenorphine treatment of opioid dependence, and 
that doctors should follow indications related disorders 
arising from BZD abuse and need to treat these 
patients appropriately. Pharmacodynamic interactions 
especially when two or more drugs which are able to 
produce similar pharmacological effects are taken at 
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the same time, can result in significant adverse 
effects, such as buprenorphine and alprazolam inject 
together resulting deaths are thought to be associated 
with depression central nervous system (CNS) and 
reduced breathing (fatal respiratory depression) [19]. 
There is a significant rate of relaps of taking BZD after 
a certain period in long-term users of BZD [20]. 
Sedatives such as benzodiazepines are the 
most commonly prescribed drugs for the treatment of 
insomnia in people addicted to drugs, but also to most 
other people. Benzodiazepine use is associated with 
patient characteristics, mostly female, with the use of 
analgesics and anti-depressants, and the presence of 
cancer in particular or chronic heart failure [21].  
This paper aims to point out the trend of the 
use of BZD nationwide for over 10 years with special 
emphasis on the type, quantity and proportion of 
drugs issued by the group of BZD prescription versus 
total amounts of benzodiazepines used in the country. 
 
Materials and Methods 
The research presents an analytical cross-
sectional study conducted from January to March 
2014. The study analyzes the available data on the 
use of benzodiazepines in the country. This study 
used several sources of data: Statistical Reports of 
the United Nations regarding the consumption of 
psychotropic substances of all countries in the world 
including MKD; Data from the Ministry of Health, 
associated with use of drugs from the group of 
benzodiazepines (BZD), derived from reports of 
stakeholders in MKD in format for reporting to the 
United Nations, the coverage period is 2003-2013 ; 
Data extracted from the database of the Ministry of 
Health on the basis of MKD prescribed and 
implemented electronic prescriptions registered in 
database "My term" period of coverage June 2013 - 
May 2014; analysis reports of the Health Insurance 
Fund from the period 2008-2013.  
 
Statistical processing 
Descriptive statistical method was applied for 
processing quantitative data. The data obtained from 
the survey were processed in Excel (data analysis), 
version 10, and are presented in tables and graphics. 
 
Results 
The analysis showed that, in the country, over 
a period of 10 years, from a group of 
benzodiazepines, with different dynamics expressed 
in popularity and use, the following psychotropic 
substances are circulating: Alprazolam, Bromazepam, 
Diazepam Klorazepat, Flurazepam, Lorazepam, 
Medazepam, Midazolam, Nitrazepam, Prazepam, 
Tetrazepam. 
In accordance with Anatomical and 
Therapeutic Classification of medicines (ATC) 
introduced by the World Health Organization, BZD are 
classified in: first group N05BA, which implies N 
nervous system, N05 psyholeptics, N05B ansyolitics, 
N05BA benzodiazepine derivatives. This group 
includes: diazepam N05BA01 the defined daily dose 
DDD [22] of 10 mg; bromazepam N05BA08 the 
defined daily dose of 10 mg; lorazepam N05BA06 the 
defined daily dose of 2.5 mg, with a daily medazepam 
N05BA03 defined dose of 20 mg; prazepam 
N05BA011 the defined daily dose of 30 mg, and group 
2 N05S hypnotics and sedatives N05CD 
benzodiazepin derivatives including flurazepam 
N05CD01 the defined daily dose of 30 mg; midazolam 
N05CD08 the defined daily dose of 15 mg; Group 
three N03BX07muskulni tetrazepam relaxants. 
Analysis of data from the Ministry of Health associated 
with the use of drugs from the group of 
benzodiazepines (BZD), derived from reports of drug 
agents in MKD format for reporting to the United 
Nations, the coverage period 2003-2013, points that 
(Table 1) the most utilized in the MKD is a drug 
Diazepam, with more than half of all amounts used 
BZD. 
 
Table 1: Summary of quantities used BZD in MKD year period from 2003 to 2013 (kg). 
 
Aprazolam Bromazepam Diazepam Clorazepate Flurazepam Lorazepam Medazepam Midazolam Nitrazepam Prazepam Tetrazepam Total 
2003 
1 1 253 0 4 7 22 4 1 26 0 319 
0,3% 0,3% 79,3% 0,0% 1,3% 2,2% 6,9% 1,3% 0,3% 8,2% 0% 7% 
2004 
1,5 193 148 2 7 5 10 1 1 24,44 0 392,94 
0,4% 49,1 37,7% 0,5% 1,8% 1,3% 2,5% 0,3% 0,3% 6,2% 0,0 8,7% 
2005 
2,4 85 173 1 6,4 8 17 0 0,05 42 0 334,85 
0,7% 25,4% 51,7% 0,3 1,9% 2,4% 5,1% 0,0 0,0 12,5% 0,0 7,4% 
2006 
3 87 180 0 7 9 10 0,5 0,1 43 0 339,6 
0,9% 25,6% 53,0% 0,0 2,1% 2,7% 2,9% 0,1% 0,0 12,7% 0,0 7,5% 
2007 
5 99 221 0 8 17 6 0 0,3 34 0 390,3 
1,3% 25,4% 56,6% 0,0 2,0% 4,4% 1,5% 0,0 0,1% 8,7% 0,0 8,6% 
2008 
7 145 286 0 10,47 7 17 1 0,77 30 0 504,5 
1,4% 28,8% 56,7% 0,0 2,1% 1,4% 3,4% 0,2% 0,2% 5,9% 0,0 11% 
2009 
8 94 306 0 9 10 13 1 1 50 0 492 
1,6% 19,1 62,2% 0,0 1,8% 2,0% 2,6% 0,2% 0,2% 10,2% 0,0 11% 
2010 
9 104 103 0 9 9 1 1 0,3 47 1 284,3 
3,2% 36,6% 36,2% 0,0 3,2% 3,2% 0,4% 0,4% 0,1% 16,5% 0,4 6,3% 
2011 
8 138 328 0 8 11 12 1 1 38 2,5 547,5 
1,5% 25,2% 59,9% 0,0 1,5% 2,0% 2,2% 0,2% 0,2% 6,9% 0,5% 12% 
2012 
9 63 165 0 11 23 15 0,4 0,55 62 2 350,95 
2,6% 18,0% 47,0% 0,0 3,1% 6,6% 4,3% 0,1% 0,2 17,7% 0,6% 7,8% 
2013 
8 193 301 0 5,34 3,2 8,43 0,4 0,5 22 1,16 543,03 
1,5% 35,5% 55,4% 0,0 1,0% 0,6% 1,6% 0,1% 0,1% 4,1% 0,2% 12% 
TOTAL 
61,9 1202 2464 3 85,24 95.34 131.43 10.3 6,8 418,44 6,66 4498,9 
1,4% 26,7% 54,8% 0,1% 1,9% 2,1% 2,9% 0,2% 0,2% 9,3% 0,1% 100% 
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With the emergence of BZD group of drugs, 
barbiturates because of their greater toxic and 
dependence predisposition are largely dismissed. 
Beside that, the drug Phenobarbital representative 
group of barbiturates is still in use in MKD and 
worldwide. As part of the analysis is a comparison of 
three generations of drugs, such as: the use of 
phenobarbital versus BZD as a group of drugs that 
eradicate the use of barbiturates group; BZD group 
and the new group of drugs called non-
benzodiazepines or "Z-drugs", which are developed in 
order to replace BZD to offer safer treatment for 
patients with fewer side effects. Non-benzodiazepines 
are a class of psychoactive drugs that are very similar 
to benzodiazepines, almost entirely the same as 
benzodiazepines pharmacodynamics, and completely 
different chemical structure and therefore not 
associated with benzodiazepines at the molecular 
level [23]. These drugs are sedatives and are used 
exclusively for the treatment of mild insomnia. They 
are safer than the older barbiturates, in particular in 
predisposition for overdose; in comparison with 
benzodiazepines have fewer tendencies to induce 
physical dependence, although these issues are not 
yet fully confirmed, as noted side effects like amnesia 
and rarely hallucinations [24]. The analysis showed 
that the amount of use of Phenobarbital in MKD is the 
second most utilized BZD between bromazepam and 
diazepam first (Figure 1). 
 
Figure 1: The use of Diazepam and Bromazepam group of BZD, 
Phenobarbital group barbiturates and zolpidem group Z-drug period 
2003-2013. 
 
Diazepam is convincingly the most commonly 
used preparation of drugs for the pharmacological 
indication. A decline is shown in use over the period 
2004-2006, when dominance have the barbiturates 
phenobarbital and oscillations of use is shown in 2010 
and 2011. 
 
Figure 2: Trend of use of Prazepam, Medazepam, Lorazepam, 
Flurazepam, Alprazolam 2003-2013. 
Analysis of the use of BZD shown that despite 
Diazepam and Bromazepam, Alprazolam, 
Flurazepam, Lorazepam, Medazepam, Prazepam are 
significantly used. The ratio of the use of these five 
BZD during the ten years analyzed is: Prazepam 36%, 
11% Medazepam, Lorazepam use 9%, 7% 
Flurazepam, and 5% use of Alprazolam. 
While the use of Flurazepam and Alprazolam 
is constant, with a slight gradual increase until 2012, 
use of Lorazepam increased in 2007 by 7.4% as a 
percentage of use of 8.3% in 2006, and the level of 
use in 2007 was 15.6%. Then use declines of 6.4% 
which decreased by 9.2%. It also marks another peak, 
increased use of Lorazepam in 2012 by 10% and it is 
21%. The use of Medazepam seen several oscillation 
and in 2004 declined the use of 9% and it was 7.6%, 
then increased in 2005 by 5.3% and amounted to 13% 
after a slight decline again, following growth use in 
2008 and it stands at 12.9%, and in 2010 registered a 
sharp drop in the use of Medazepam 9%. Oscillation 
shows the use and re-growth in 2012 when it reached 
11.4% of use of BZD. The use of Prazepam is 
relatively stable and high, 3 observed oscillations and 
a small decline in the level of 5.6% in 2004, a period 
of stable continuous level of usage and peak in 2010 
to a level of 11.4% in 2009 and 14% in 2012. Noted 
that all five BZD use declined in 2013 and 2% of 
Alprazolam, Flurazepam 7%, down from 18% 
Lorazepam, 5% and 5% Medazepam, Prazepam. 
 
 
Figure 3: Trend in the use of diazepam and bromazepam 2003-
2013. 
 
The ratio of use of the two most used BZD in 
MKD is diazepam 70%, versus 30% bromazepam. 
The use of diazepam in the analyzed ten years is 
continuously high, with some oscillations observed: in 
2004 decreased by 10% and use level reaches 30%, 
then gradually to grow by 5% on 2005, then an 
additional 1.4% in 2006, increased by an additional 
8.3% in 2007 and 13% in 2008, to reach high peak of 
62% of use in 2009. Then there has been a sharp 
decline from 40% of use in 2010 and reaching a 
record low level of use of 20.9%. In 2011 the use 
marks a big change again this time with an increase of 
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45.5% and reaching the highest level of use of 66.4%. 
In 2012 recorded a re-oscillation by reducing the use 
of 33% to reach the level of use in 2013 of 60.9%.  
The use of Bromazepam is with oscillations also, but 
not so strong peaks as in the case of Diazepam. High 
use in 2004 of 39% dropped to 17% and keeping the 
use of these scales to more significant growth in 2008 
year and achieving a level of 29.4%, then re-drop from 
10% in 2009 and growth in 2011 increased by 8.9% 
and reaching the level of 27.9%, re-oscillation is 
recorded in 2012 declined the use of 15%, and again 
increase of 26.3% in 2013 and reaching the level of 
39% usage. 
In terms of the prescriptions of BZD at the 
pharmacy, in the analyzed period of 12 months (June 
2013-May 2014) time when the electronic database of 
the Ministry of Health "My term" was introduced, the 
most prescribed and also released most of the 
prescription drugs from the group of a BZD are: 
diazepam 5 mg of 59%, 2mg of 40% and 1% of 10 mg 
(Table 2). 
 
Table 2: Summary of three most prescribed BZD monthly and pharmaceutical ratio of strength versus drug Phenobarbital. 
 
2013 2014 
June  July August  September October  November  December January  February March  April  May 
Total 
 
bromazepam 1,5 mg 29 1183 2719 3298 3789 3750 4008 3718 3745 3989 4159 2087 36474 
bromazepam 3 mg 124 5410 13590 16149 18394 18405 19715 18648 18376 19387 19663 11039 178900 
bromazepam 6 mg 20 563 1351 1673 1763 1817 1891 1814 1849 2034 1932 1159 17866 
Total 173 7156 17660 21120 23946 23972 25614 24180 23970 25410 25754 14285 233240 
diazepam 10 mg 1 156 423 528 601 583 578 539 525 585 566 351 5436 
diazepam 2 mg 1 5430 17638 22520 25836 26238 27536 26616 26604 27953 28549 15373 250294 
diazepam 5 mg 152 10877 28542 34414 38085 37774 40354 39193 38267 40222 41501 22731 372112 
Total 154 16463 46603 57462 64522 64595 68468 66348 65396 68760 70616 38455 627842 
phenobarbital 100 mg 7 795 2641 3051 3395 3434 3614 3418 3385 3418 3434 2038 32630 
phenobarbital 15 mg 1 91 113 160 150 146 130 150 155 132 136 50 1414 
Total 8 886 2754 3211 3545 3580 3744 3568 3540 3550 3570 2088 34044 
alprazolam 0,25 mg 84 3736 9443 11539 12823 13328 13921 14044 13783 14667 14958 7610 129936 
alprazolam 0,5 mg 123 6041 15687 18306 20313 20396 21930 21398 20942 22210 22511 12096 201953 
alprazolam 1 mg 4 316 874 1056 1156 1112 1224 1199 1222 1265 1241 717 11386 
Total 211 10093 26004 30901 34292 34836 37075 36641 35947 38142 38710 20423 343275 
 
With regard to Bromazepam (Table 2), the 
most prescribed bromazepam is 3mg of 76%, 
bromazepam 1.5 mg is 16.6% and bromazepam 6mg 
is 7.6%. Alprazolam 0.5 mg is prescribed 58.8%, 
37.9% is alprazolam 0.25%; and from alprazolam 1 
mg is 3.3%. Drug from the group of barbiturates, 
phenobarbital in measure of 100mg is used 96% vs. 
4% application of 15 mg of phenobarbital. Data on 
consumption of drugs in the related months are 
important indicators that can be applied to analyze 
additional epidemiological studies regarding morbidity 
in certain structures in the population and comparison 
with data available from other countries. 
 
Figure 4: Overview of realized prescription drugs from BZD group 
within 12 months. 
 
Of all the prescriptions and prescribed drugs 
issued by the group of BZD processed in the 
database of the Ministry of Health from 2013 when it 
was introduced, most prescribed BZD for a period of 
12 months was 50.7% with diazepam, Alprazolam 
with 27.7% and 18.8% of Bromazepam prescriptions 
in this category. Phenobarbiton, the product of a 
group of barbiturates, has coverage of 1.7% of the 
prescribed recipes. These data are relevant for 
comparison between the total issued and 
implemented prescription drugs registered in the 
electronic database "My term", used for the total 
amount of BZD in the country, thus gaining a clear 
picture of how drugs are taken with a prescription. 
Certainly, the data will be complete when the new 
base will be processing quantities of BZD used 
internally at a clinics and hospital facilities for the 
treatment of patients. These data are not included, 
yet.  
According to the Fund [25], the second 
number of prescription medicines carried by the action 
of the central nervous system (ATC group "N"), which 
also have a significant increase in the structure of the 
total issued drugs from 13% in 2008 to 15% in 2011. 
The period of analysis 2008-2013, according to the 
Fund, diazepam is second the most prescribed 
medicines and alprazolamot is in the tenth place, all of 
which are medicines authorization for circulation in 
MKD. 
 
Figure 5: Top most prescribed drugs in MKD, according to the 
Health Insurance Fund. 
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This review is important to realize that 
according to available data from Health Insurance 
Fund database, two drugs from the group of BZD, in 
the period of 6 years, are the most used drug of all 
pharmacological groups in comparison with all 
medical needs. 
 
 
Discussion 
 
The aim of this study was to analyze the 
prevalence of the use of benzodiazepines in the 
country. The analysis showed a high prevalence of 
BZD use, especially diazepam. The analysis pointed 
out the difference in the amounts of data on BZD use 
in MKD and demand in terms of BZD prescriptions 
issued. Data on the use for ex. of bromazepam is 
extremely high, and the number of prescriptions 
issued alprazolam, indicates that a significant 
percentage of more substance prescribed by 
bromazepam. The obtained data indicate lack of 
prescriptions for medicine prazepam in the pharmacy 
although the quantities of used prazepam, according 
to the database are substantial. These data suggests 
reasonable thinking and considering the use of drugs 
from the group of BZD without prescription. 
If we take into account long analysis of the 
Fund from 2008 in comparison with the new electronic 
data base of the Ministry of Health, observed situation 
with Alprazolam and Bromazepam is the same in the 
two data bases. 
In this context especial concerns are some 
data from the MKD ESPAD study that confirmed that 
students and youth less than 9 years old age have 
access to BZD which is not prescribed by a doctor. In 
MKD ESPAD study [26], carried out in 1999 and 2008 
with coverage of the whole territory of MKD, and in 
2012 only city of Skopje was covered. The study of 
2008 among other results found that: 10.1% of 
students had used tranquillizers at least once in life, 
so they are usually try out illicit substance among 
students. More girls (11.2%) than students (9.1%) 
used tranquillizers. For comparison MKD is far above 
the EU average of 6%. In the same line is using 
sedatives and tranquillizers only Poland and Lithuania 
[27]. It should be noted that medical prescriptions for 
tranquillizers doubled since 1999. Data for 2012 from 
the ESPAD coverage only city of Skopje suggest that 
drinking sedatives on the recommendation of a 
physician 6.6% for less than 3 weeks and 2.5% for 
more than 3 weeks. 4.5% of students reported using 
sedatives medical doctor .The age of use of 
unsubscribed sedatives is 9god or less at 0.87%; 10 
years at 0.17%; 11 years. 0.35%; 12 years. 0.70%; 13 
years. 0.87%; 14 years. 1.22%; 15 years 2.27%. 
Benzodiazepines are a group of CNS 
depressants, causing a feeling of calm (anxiolysis), 
drowsiness and sleep, widely used in medicine to 
treat anxiety (anxiolytics) and insomnia (sedative / 
hypnotics), and other psychological conditions, such 
as seizures panic and panic disorder [28], it is widely 
prescribed BZD drugs in developed countries [29-30]. 
In France, 30% of people aged 65 years and over use 
of BZD [31]. They are used by more than 20% of 
people aged 65 and over in Canada and Spain, and 
15% of those in Australia [32-34]. The use of BZD is 
high among the elderly in the U.S. and the UK [35-36].  
European prevalence studies shows that, with 
the exception of alcohol, benzodiazepines cannabis 
with psychoactive substances are mostly detected 
among drivers. Experimental studies show that these 
drugs impair the ability to drive and when alcohol is 
used at the same time, the risk of being involved in an 
accident is greatly increased [37]. EU survey 
prevalence of the risk of injury in traffic management 
under the influence of psychoactive means noticed 
differences between the EU and BZD drugs were 
mainly found in older female drivers during daylight 
hours [38]. Epidemiological studies have shown that 
women are generally more likely to have changes in 
mood and anxiety disorders than men [39-41]. 
 In conclusion, the analysis in the paper shows 
that the use of BZD in MKD is particularly high. In the 
same time, limited number of studies was performed 
in MKD for this kind of drugs and their effects, still 
remains unclear which are the drivers for their use; 
differences in use between the gender; use of BZD by 
pregnant woman, use of BZD in the adult population. 
There is need for additional focused research that will 
contribute to developing a full picture of the situation. 
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